(Q51201612)

English

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID).

scientific article published in October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

0 references

1 reference

based on heuristic

inferred from title

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

5

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

13

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

Gerd-Rüdiger Burmester

6

object named as

G Burmester

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

Christof Specker

0 references

author name string

M Witt

1

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

M Grunke

2

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

F Proft

3

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

M Baeuerle

4

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

G Chehab

7

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

C Fiehn

8

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

R Fischer-Betz

9

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

M Fleck

10

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

K Freivogel

11

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

M Haubitz

12

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

S Lovric

14

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

C Metzler

15

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

A Rubberth-Roth

16

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

A Schwarting

17

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

C Specker

18

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

H-P Tony

19

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

L Unger

20

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

S Wassenberg

21

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

T Dörner

22

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

H Schulze-Koops

23

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

German Registry of Autoimmune Diseases (GRAID) Investigators

24

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

publication date

1 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

22

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

11

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

1142-1149

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

B-cell targeting in rheumatoid arthritis and other autoimmune diseases

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

B-cell-directed therapies for autoimmune disease

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Novel approaches to therapy for systemic lupus erythematosus: update 2005.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

An open study of B lymphocyte depletion in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Rituximab-it was the best of times, it was the worst of times.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Rituximab - shadow, illusion or light?

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Long-term follow-up in lupus nephritis patients treated with rituximab--clinical and histopathological response

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Current and novel therapeutics in the treatment of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

A systematic review of the off-label use of biological therapies in systemic autoimmune diseases

1 reference

https://api.crossref.org/works/10.1177%2F0961203313503912

21 January 2018

Identifiers

10.1177/0961203313503912

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/24057058

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51201612&oldid=1967389716"